Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Second Sight Medical Products's annualized net income for the quarter that ended in Jun. 2022 was $-12.30 Mil. Second Sight Medical Products's average shareholder tangible equity for the quarter that ended in Jun. 2022 was $64.61 Mil. Therefore, Second Sight Medical Products's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2022 was -19.04%.
The historical rank and industry rank for Second Sight Medical Products's Return-on-Tangible-Equity or its related term are showing as below:
EYESW'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -648.56 Med: -288.46 Max: -13.37
Current: -13.37
During the past 10 years, Second Sight Medical Products's highest Return-on-Tangible-Equity was -13.37%. The lowest was -648.56%. And the median was -288.46%.
EYESW's Return-on-Tangible-Equity is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 4.08
vs EYESW: -13.37
Second Sight Medical Products (NAS:EYESW) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Second Sight Medical Products Return-on-Tangible-Equity Related Terms
Second Sight Medical Products Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Second Sight Medical Products Return-on-Tangible-Equity Chart
EYESW vs SONX, LUCD, LHDX: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Second Sight Medical Products's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Second Sight Medical Products Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Second Sight Medical Products's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Second Sight Medical Products's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2022) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -19.04% mean?
Second Sight Medical Products (EYESW) has a Return-on-Tangible-Equity of -19.04% as of Jun. 2022. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Second Sight Medical Products and its competitors.
Is Second Sight Medical Products' Return-on-Tangible-Equity too high?
Second Sight Medical Products' current Return-on-Tangible-Equity is -19.04%.
How does Second Sight Medical Products' Return-on-Tangible-Equity compare to SONX and LUCD?
Second Sight Medical Products' Return-on-Tangible-Equity of -19.04% can be compared against companies in the Medical Devices & Instruments industry. The industry median Return-on-Tangible-Equity is 4.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.08, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Second Sight Medical Products and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Second Sight Medical Products's current Return-on-Tangible-Equity is -19.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Second Sight Medical Products stock overvalued right now?
Second Sight Medical Products (EYESW) has a current Return-on-Tangible-Equity of -19.04%. The current Return-on-Tangible-Equity is -19.04%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Second Sight Medical Products (EYESW), the current Return-on-Tangible-Equity is -19.04% as of Jun. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Second Sight Medical Products Business Description
Second Sight Medical Products Inc develops, manufactures, and markets implantable prosthetic devices to create an artificial form of useful vision for blind individuals. The company's product Argus II System treats outer retinal degenerations, such as Retinitis Pigmentosa, often referred to as RP. The company generates revenue from the sale of its Argus II retinal prosthesis systems, which include the implant and external components. Geographically, the company operates in the United States, Italy, China, and of which key revenue is derived from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EYESW has been successfully added to your 